Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • AYUSH
    • AYUSH ministry...

    AYUSH ministry introduces scheme for monitoring drugs safety aspects

    Written by Ruby Khatun Khatun Published On 2018-08-19T10:30:14+05:30  |  Updated On 19 Aug 2018 10:30 AM IST
    AYUSH ministry introduces scheme for monitoring drugs safety aspects

    New Delhi: The AYUSH Ministry introduced a new central sector scheme for monitoring of the safety aspects of Ayurveda, Siddha, Unani and Homoeopathy drugs and documenting their adverse effects.


    The ministry introduced the scheme for promoting pharmacovigilance of these drugs.


    "The prime objective of the scheme is to develop the culture of documenting adverse effects and undertake safety monitoring of Ayurveda, Siddha, Unani and Homoeopathy drugs and surveillance of misleading advertisements appearing in the print and electronic media," it said.


    The scheme intends to facilitate the establishment of a three-tier network of National Pharmacovigilance Centre (NPvCC), Intermediary Pharmacovigilance Centres (IPvCCs) and Peripheral Pharmacovigilance Centres (PPvCC), an official statement said.


    All India Institute of Ayurveda, New Delhi, an autonomous body under the AYUSH Ministry, was designated as the National Pharmacovigilance Centre for coordinating various activities under the initiative.


    In the initial phase of implementation, five national institutes of AYUSH are designated as the Intermediary Pharmacovigilance Centres and 42 institutions of AYUSH having clinical facilities as peripheral pharmacovigilance centers to take up the work of reporting, documentation, analysis, causality assessment of the adverse reactions and events associated with the consumption of such drugs.


    The scheme was rolled out for implementation in the country near the end of the financial year 2017-18.


    It is intended to have more such centers across the country and achieve the target of 100 peripheral pharmacovigilance centers by 2020.


    The government in the first instance has sanctioned a grant of Rs 10.60 crore to All India Institute of Ayurveda, New Delhi to establish the proposed pharmacovigilance network and steer implementation of the initiative with standard protocol and reporting format, training of coordinators.


    Representatives of Central Drug Standards Control Organisation as the national drug regulatory authority and the Indian Pharmacopoeia Commission being the WHO Collaborating Centre for Pharmacovigilance in the country are associated in the initiative as mentor and guide.

    AyurvedaAyushAyush MinistryCentral Drug Standards Control Organisationdrugs safety aspectsHomoeopathy drugsIntermediary Pharmacovigilance Centresintroducesmisleading advertisementsMonitoringNational Pharmacovigilance CentrePeripheral Pharmacovigilance CentrespharmacovigilanceschemeSiddhasurveillanceUnaniWHO
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok